Ovarian carcinoma screening in women at intermediate risk: Impact on quality of life and need for invasive follow-up

Cancer

Volumn 104, Issue 2, 2005, Pages 314-320

  Kauft, Noah D ^a   Hurley, Karen E ^a   Hensley, Martee L ^a   Robson, Mark E ^a   Lev, Gali ^a   Goldfrank, Deborah ^a   Castiel, Mercedes ^a   Brown, Carol L ^a   Ostroff, Jamie S ^a   Hann, Lucy E ^a   Offit, Kenneth ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CA 125; Familial risk; Ovarian carcinoma; Quality of life; Screening; Ultrasound

Indexed keywords

CA 125 ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; BREAST CARCINOMA; CANCER SCREENING; ENDOMETRIUM BIOPSY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENOPAUSE; ONCOGENE; OVARIAN BLEEDING; OVARY CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; SHORT FORM 36; TRANSVAGINAL ECHOGRAPHY;

CA-125 ANTIGEN; FAMILY HEALTH; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 22244460786     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21148     Document Type: Article

References (31)

1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
2. National Institutes of Health. Ovarian cancer: screening, treatment, and followup. NIH Consensus Statement 1994; 12:1-30.
3. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2- Cancer Genetics Studies Consortium. JAMA. 1997;277:997-1003.
4. The National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Clinical practice guidelines in oncology. Version 1. 2004. Available from URL: http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp [accessed November 2004].
5. Bergfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet. 2002;360:891-894.
6. Van Nagell JR, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening of asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77: 350-356.
7. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353:1207-1210.
8. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100:1413-1416.
9. Hensley ML, Castiel M, Robson ME. Screening for ovarian cancer: what we know, what we need to know. Oncology (Huntingt). 2000;14:1601-1607.
10. Hensley ML, Robson ME, Kauff ND, et al. Pre- and post-menopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecol Oncol. 2003;89:440-446.
11. McHorney CA, Ware JE Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;3:247-263.
12. Weiner Z, Thaler I, Beck D, Rottem S, Deutsch M, Brandes JM. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol. 1992; 79:159-162.
13. Karlan BY, Raffel LJ, Crvenkovic G, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol. 1993;169:494-501.
14. Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer. 1995;76:1214-1218.
15. Bourne TH, Campbell S, Reynolds K, et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994;52:379-385.
16. Salsman JM, Pavlik E, Boerner LM, Andrykowski MA. Clinical, demographic, and psychological characteristics of new, asymptomatic participants in a transvaginal ultrasound screening program for ovarian cancer. Prev Med. 2004;39: 315-322.
17. Wardle FJ, Pope R. The psychological costs of screening for cancer. J Pscyhosom Res. 1992;35:609-624.
18. Wardle FJ, Collins W, Pernet AL, et al. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst. 1993;85:653-657.
19. Ware J, Kosinski M. SF-36 Physical and Mental Health Summary Scales: a manual for users Diversion l. 2nd edition. Lincoln, RI: QualityMetric Inc., 2001.
20. Phillips RC, Lansky DJ. Outcomes management in heart valve replacement surgery: early experience. J Heart Valve Dis. 1992;1:42-50.
21. Schwartz, LM, Woloshin S, Fowler FJ Jr., Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004; 291:71-78.
22. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56:265-271.
23. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-1316.
24. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-1268.
25. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol. 1999;17:2050-2054.
26. Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000;18:3464-3470.
27. Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003;91:154-159.
28. Barakat RR. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. J Clin Oncol. 1999;17: 1967-1968.
29. Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists. ACOG committee opinion: tamoxifen and endometrial cancer. Int J Gynaecol Obstet. 2001;73:77-79.
30. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
31. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.